Janus Henderson Group Discloses 10.6% Passive Stake In Mirum Pharmaceuticals As Of June 28
$JHG
$MIRM
Investment Managers
Finance
Biotechnology: Pharmaceutical Preparations
Health Care
- Form 13G
- Form 13G
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 2/18/2026 | $130.00 | Outperform | RBC Capital Mkts | |
| 10/3/2025 | $52.00 | Outperform | BMO Capital Markets | |
| 9/24/2025 | $95.00 | Buy | TD Cowen | |
| 8/11/2025 | $89.00 | Buy | Stifel | |
| 5/19/2025 | $73.00 | Buy | H.C. Wainwright | |
| 4/3/2025 | $43.00 | Neutral → Buy | BofA Securities | |
| 2/24/2025 | $45.00 → $50.00 | Neutral → Buy | UBS | |
| 2/5/2025 | $44.00 → $53.00 | Neutral → Overweight | Analyst |
RBC Capital Mkts initiated coverage of Mirum Pharmaceuticals with a rating of Outperform and set a new price target of $130.00
BMO Capital Markets initiated coverage of Janus Henderson Group with a rating of Outperform and set a new price target of $52.00
TD Cowen initiated coverage of Mirum Pharmaceuticals with a rating of Buy and set a new price target of $95.00
PRE 14A - JANUS HENDERSON GROUP PLC (0001274173) (Filer)
SC 13E3/A - JANUS HENDERSON GROUP PLC (0001274173) (Subject)
DEFA14A - JANUS HENDERSON GROUP PLC (0001274173) (Filer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
Janus Henderson (NYSE:JHG), today announced it has launched the Janus Henderson US Equity Enhanced Income ETF (JUDO). This ETF aims to generate current income by actively investing in primarily dividend-paying equities, while seeking risk reduction and additional income from an opportunistic covered call option strategy. JUDO, managed by Portfolio Manager Jeremiah Buckley, CFA, seeks to deliver an actively managed portfolio of high-quality companies — defined by revenue growth, earnings growth and increasing dividends, while aiming to provide dampened volatility. The team believes these companies can participate in market gains while being resilient on the downside. "JUDO's options stra
Provides Compelling Value to Janus Henderson Shareholders at Attractive Premium in an Uncertain Environment Transaction Remains on Track to Close in Mid-2026 Trian Fund Management, L.P. and its affiliated funds ("Trian") and General Catalyst Group Management, LLC and its affiliated funds ("General Catalyst"), today confirmed that they amended the definitive merger agreement with Janus Henderson Group plc (NYSE:JHG), under which Trian and General Catalyst will now acquire Janus Henderson for $52.00 per share in cash. This represents Trian and General Catalyst's best and final offer. The amended purchase price represents a $3.00 increase in cash over the original $49.00 per share in cas
Amended Merger Agreement Represents a $3.00 All-Cash Price Increase; 25% Premium to Unaffected Share Price; Parties Committed to Closing by Mid-2026 Special Committee Determines that Victory Capital's Revised Unsolicited March 17, 2026 Proposal Is Not Actionable and Is Not in Best Interests of Janus Henderson and Its Shareholders Amended Merger Agreement's All-Cash Transaction With Trian and General Catalyst Is Superior From an Expected Value and Certainty Perspective and Is the Only Actionable Proposal Janus Henderson Group plc (NYSE:JHG, "Janus Henderson, " or the "Company")) announced that Trian Fund Management, L.P. and its affiliated funds ("Trian"), General Catalyst Group Manage
For Immediate Release: February 21, 2025 Today, the U.S. Food and Drug Administration approved Ctexli (chenodiol) for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Ctexli is the first FDA-approved drug to treat CTX, a very rare lipid storage disease.“The FDA is dedicated to supporting new drug development for rare diseases including very rare metabolic diseases like cerebrotendinous xanthomato
Richard Bernstein Advisors (RBA) is a research-driven, macro multi-asset investment manager delivering differentiated investment solutions, overseeing approximately $20 billion in client assets1 Acquisition positions Janus Henderson as a leading model portfolio and separately managed account (SMA) provider Janus Henderson Group (NYSE:JHG) ("Janus Henderson" or the "Company"), a leading global asset manager, today announced it has entered into a definitive agreement to acquire 100% of Richard Bernstein Advisors ("RBA"), a research-driven, macro multi-asset investment manager. The acquisition positions Janus Henderson as a leading model portfolio and separately managed account (SMA) pr
Janus Henderson Group plc (NYSE:JHG) ("Janus Henderson" or the "Company") today announced that the independent special committee (the "Special Committee") of the Company's board of directors (the "Board") has retained Goldman Sachs & Co. LLC as its financial advisor and Wachtell, Lipton, Rosen & Katz as its legal counsel. The Special Committee was formed to evaluate the previously announced non-binding proposal letter from Trian Fund Management, L.P. and its affiliated funds ("Trian") and General Catalyst Group Management, LLC and its affiliated funds ("General Catalyst") received by the Board on October 26, 2025 (the "Proposal"). Janus Henderson does not intend to comment on the Propos
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced the appointment of Doug Sheehy, JD, as chief legal officer. Mr. Sheehy brings nearly two decades of experience leading global legal and compliance operations for biopharmaceutical companies. Mr. Sheehy was most recently chief legal officer and secretary at Sonoma Biotherapeutics, Inc., which is developing regulatory T cell therapies for autoimmune and inflammatory diseases. Prior to Sonoma, from 2016 to 2020, he served as general counsel and secretary for Aimmune Therapeutics, Inc., a biopharmaceutical company that specialized in the development and commercialization of treatments for life-threatening food allergies. Mr. Sheehy serv
SC 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
SC 13G/A - JANUS HENDERSON GROUP PLC (0001274173) (Filed by)
SC 13G/A - JANUS HENDERSON GROUP PLC (0001274173) (Filed by)
Janus Henderson (NYSE:JHG), today announced it has launched the Janus Henderson US Equity Enhanced Income ETF (JUDO). This ETF aims to generate current income by actively investing in primarily dividend-paying equities, while seeking risk reduction and additional income from an opportunistic covered call option strategy. JUDO, managed by Portfolio Manager Jeremiah Buckley, CFA, seeks to deliver an actively managed portfolio of high-quality companies — defined by revenue growth, earnings growth and increasing dividends, while aiming to provide dampened volatility. The team believes these companies can participate in market gains while being resilient on the downside. "JUDO's options stra
Amended Merger Agreement Represents a $3.00 All-Cash Price Increase; 25% Premium to Unaffected Share Price; Parties Committed to Closing by Mid-2026 Special Committee Determines that Victory Capital's Revised Unsolicited March 17, 2026 Proposal Is Not Actionable and Is Not in Best Interests of Janus Henderson and Its Shareholders Amended Merger Agreement's All-Cash Transaction With Trian and General Catalyst Is Superior From an Expected Value and Certainty Perspective and Is the Only Actionable Proposal Janus Henderson Group plc (NYSE:JHG, "Janus Henderson, " or the "Company")) announced that Trian Fund Management, L.P. and its affiliated funds ("Trian"), General Catalyst Group Manage
- 2025 net product sales of $521 million - 2026 expected global net product sales of $630 million to $650 million - Volixibat VISTAS study in PSC topline data expected Q2 2026 - LIVMARLI® EXPAND study in additional cholestatic pruritus settings topline data expected Q4 2026 - Brelovitug AZURE-1 and AZURE-4 studies in HDV topline data expected H2 2026 - Conference call to provide business updates today, February 25 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today reported financial results for the fourth quarter and year-end 2025 and provided a business update. "2025 was a year of meaningful progress and execution for